RWJ 27755

Drug Profile

RWJ 27755

Alternative Names: PPACK

Latest Information Update: 18 May 1995

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Johnson & Johnson Pharmaceutical Research & Development LLC
  • Class Antiplatelets; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 18 May 1995 Discontinued-Preclinical for Thrombosis in USA (Unknown route)
  • 20 Dec 1994 An in vivo study has been added to the Thromboses pharmacodynamics section
  • 30 Nov 1994 An in vivo study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top